CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

 

patiromer (Veltassa)

Therapeutic Area: Hyperkalemia, adults (chronic kidney disease)
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation

Submit Feedback

 

semaglutide (Rybelsus)

Therapeutic Area: diabetes mellitus, type 2
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation

Submit Feedback

 

luspatercept (Reblozyl)

Therapeutic Area: beta-thalassemia associated anemia
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation

Submit Feedback

 

dupilumab (Dupixent)

Therapeutic Area: Asthma
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation

Submit Feedback

 

risdiplam (Evrysdi)

Therapeutic Area: Spinal muscular atrophy
Draft recommendations posted for stakeholder feedback: May 13, 2021
End of feedback period: May 28, 2021
Draft Recommendation

Submit Feedback

 

fedratinib (Inrebic)

Therapeutic Area: Myelofibrosis
Draft recommendations posted for stakeholder feedback: May 7, 2021
End of feedback period: May 21, 2021
Draft Recommendation

Submit Feedback

 

larotrectinib (Vitrakvi)

Therapeutic Area: Solid tumors with NTRK gene fusion
Draft recommendations posted for stakeholder feedback: May 7, 2021
End of feedback period: May 21, 2021
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Increlex (mecasermin)

Therapeutic Area: Severe primary insulin-like growth factor-1 deficiency

Call For Patient Input: May 14, 2021

Patient Input Closed: July 12, 2021

Emgality (galcanezumab)

Therapeutic Area: Prevention of migraine

Call For Patient Input: May 5, 2021

Patient Input Closed: June 28, 2021

Myinfla (colchicine )

Therapeutic Area: Atherothrombotic events in coronary artery disease

Call For Patient Input: April 29, 2021

Patient Input Closed: June 18, 2021

TBC (macitentan and tadalafil )

Therapeutic Area: Pulmonary arterial hypertension

Call For Patient Input: April 22, 2021

Patient Input Closed: June 11, 2021

Keytruda (pembrolizumab )

Therapeutic Area: Esophageal carcinoma, gastroesophageal junction adenocarcinoma

Call For Patient Input: April 14, 2021

Patient Input Closed: June 4, 2021

TBC (somatrogon )

Therapeutic Area: Growth hormone deficiency

Call For Patient Input: April 5, 2021

Patient Input Closed: May 28, 2021

TBC (tralokinumab )

Therapeutic Area: atopic dermatitis

Call For Patient Input: March 30, 2021

Patient Input Closed: May 21, 2021

TBC (abrocitinib )

Therapeutic Area: Atopic dermatitis, moderate to severe

Call For Patient Input: March 26, 2021

Patient Input Closed: May 21, 2021